Stocking epinephrine in schools improves student safety during anaphylactic emergencies, yet 74% of schools still require families to provide personal devices.
A national survey presented at the 2026 American College of Allergy, Asthma and Immunology (ACAAI) meeting reveals that schools without “stock” epinephrine are more than four times more likely to face device shortages during life-threatening allergic reactions.
Clinical Essentials for School Safety
- Epinephrine as First-Line Treatment: Epinephrine is the only medication capable of reversing anaphylaxis—a systemic, life-threatening allergic reaction.
- The “Stock” Advantage: Maintaining a supply of unassigned epinephrine (stock) ensures medication is immediately available for any student, including those with undiagnosed allergies.
- Reducing Financial Barriers: Requiring families to purchase redundant personal devices for school storage creates unnecessary financial strain, as many devices expire annually without being utilized.
The Impact of Stock Epinephrine on Emergency Response
The survey, which captured data from 349 school nurses nationwide between August and December 2025, highlights a critical gap in emergency preparedness. While 87% of schools currently maintain stock epinephrine, nearly 10% of nurses reported that the medication was unavailable during a real-world emergency. Schools lacking a dedicated stock supply were more than four times more likely to experience these critical failures.
The current standard of care often relies on a “dual coverage” approach, where schools mandate that students with known allergies provide their own auto-injectors. However, the data suggests this strategy may be inefficient. Approximately 72% of nurses reported that no student required epinephrine during the previous year, and 97% indicated that no student required more than two doses in a single day.
Mahi Singh, MD, lead study author and ACAAI member, said that having stock epinephrine available at school clearly improves student safety, since schools without it were far more likely to end up without a working device in an emergency. Singh said that while 74% of nurses prefer maintaining both personal and stock devices, the necessity of personal devices warrants further clinical scrutiny to alleviate the burden on families.
Financial and Logistical Burdens on Families
Families frequently face the recurring cost of purchasing new epinephrine auto-injectors each school year to comply with institutional policies. Because these devices have specific expiration dates, they often go unused and are discarded, costing families money.
Beyond the financial impact, maintaining personal devices in school settings can limit access to medication for students outside of school hours, as the devices are often locked away in health offices rather than remaining with the student in a backpack.
| Metric | Finding |
|---|---|
| Schools with stock epinephrine | 87% |
| Schools requiring personal devices | 74% |
| Nurses preferring dual coverage | 74% |
| Schools reporting no epinephrine use (past year) | 72% |
Epinephrine Works by Stimulating Adrenergic Receptors During Emergencies
Epinephrine is a life-saving medication with a rapid mechanism of action, primarily working by stimulating alpha- and beta-adrenergic receptors to constrict blood vessels and relax bronchial smooth muscle. There are no absolute contraindications to epinephrine administration during a true anaphylactic emergency, as the risk of death from the reaction outweighs potential side effects.
However, parents should consult with an allergist or pediatrician to develop a formal Anaphylaxis Action Plan. This document should detail specific symptoms that warrant the use of an auto-injector—such as difficulty breathing, swelling of the tongue or throat, or hives—and the appropriate follow-up care. Medical intervention is required immediately after any epinephrine administration, as a secondary “biphasic” reaction can occur hours after the initial event.
Future Trajectory for School Health Policy
Currently, only 10 states mandate that schools stock epinephrine, leaving most of the country to rely on voluntary adoption. The findings presented at the 2026 ACAAI meeting provide a strong evidence base for broader legislative support. By shifting toward universal stock programs, schools may reduce the financial and administrative friction for families while ensuring that life-saving medication is always accessible, regardless of whether a student has a previously diagnosed condition.
References
- American College of Allergy, Asthma, and Immunology (ACAAI). 2026 Annual Scientific Meeting Proceedings.
- World Health Organization (WHO). Fact Sheet: Anaphylaxis and Severe Allergic Reactions.
- Centers for Disease Control and Prevention (CDC). Managing Food Allergies in Schools.
